News

Antihistamine drug chlorcyclizine shows promise for treating HCV


 

References

Repurposing the antihistamine medication chlorcyclizine may be a viable option in the treatment of hepatitis C, reported Dr. Shanshan He and coauthors.

In a study of mice carrying human hepatocytes infected with hepatitis C virus, chlorcyclizine significantly inhibited infection of HCV genotypes 1b and 2a without drug resistance at 4 and 6 weeks of treatment (P < .05), respectively, Dr. He and associates reported.

The findings suggest that the use of chlorcyclizine in treating HCV infection may “provide a more affordable alternative to the current costly options, especially in low-resource settings where chronic HCV infection is endemic,” the investigators said in the paper.

Read the full article in Science Translational Medicine 2015 at: doi/10.1126/scitranslmed.3010286.

Recommended Reading

Human liver cells can induce antiviral reaction against hepatitis C
HCV Hub
Aetna customers to receive discount on Gilead’s hepatitis C treatment
HCV Hub
Threefold increase in cirrhosis risk with HCV
HCV Hub
Two regimens achieve high response in HCV/HIV coinfection
HCV Hub
Death rates rising for liver cancer, falling for colorectal cancer
HCV Hub
All-oral simeprevir-sofosbuvir beat interferon-based regimen for HCV with compensated cirrhosis
HCV Hub
ASCEND trial to test HCV treatment in primary care setting
HCV Hub
Novel HCV therapies found cost effective, with caveats
HCV Hub
FDA: Avoid using amiodarone with some hepatitis C antivirals
HCV Hub
New hepatitis treatment cost effective for some patient types
HCV Hub